KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Accumulated Depreciation (2021 - 2024)

Historic Accumulated Depreciation for Xenon Pharmaceuticals (XENE) over the last 4 years, with Q4 2024 value amounting to $13.5 million.

  • Xenon Pharmaceuticals' Accumulated Depreciation rose 1966.94% to $13.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $13.5 million, marking a year-over-year increase of 1966.94%. This contributed to the annual value of $13.5 million for FY2024, which is 1966.94% up from last year.
  • Xenon Pharmaceuticals' Accumulated Depreciation amounted to $13.5 million in Q4 2024, which was up 1966.94% from $11.3 million recorded in Q4 2023.
  • Xenon Pharmaceuticals' Accumulated Depreciation's 5-year high stood at $13.5 million during Q4 2024, with a 5-year trough of $8.7 million in Q4 2022.
  • Moreover, its 4-year median value for Accumulated Depreciation was $12.3 million (2021), whereas its average is $11.7 million.
  • In the last 5 years, Xenon Pharmaceuticals' Accumulated Depreciation plummeted by 3479.4% in 2022 and then surged by 2924.76% in 2023.
  • Over the past 4 years, Xenon Pharmaceuticals' Accumulated Depreciation (Quarter) stood at $13.4 million in 2021, then crashed by 34.79% to $8.7 million in 2022, then grew by 29.25% to $11.3 million in 2023, then increased by 19.67% to $13.5 million in 2024.
  • Its last three reported values are $13.5 million in Q4 2024, $11.3 million for Q4 2023, and $8.7 million during Q4 2022.